生物活性 | |||
---|---|---|---|
描述 | MI-538 stands out by inhibiting the growth of MLL leukemia cells, achieving a GI50 of 83 nM, and demonstrates specificity by not affecting the growth of HL-60 and HM-2 control cell lines, which lack MLL translocations, up to concentrations of 6 μM. This selectivity underscores its efficacy against cells transformed by MLL fusion proteins. MI-538's strong cellular activity is attributed to its low nanomolar affinity (Kd=6.5 nM) for menin, potentially enhanced by improved binding affinity and cellular uptake. Treatment with MI-538 significantly diminishes Hoxa9 and Meis1 gene expressions in MLL-AF9 cells, with about 100 nM reducing Hoxa9 expression by roughly 50% and even more substantially affecting Meis1 expression[1]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.76mL 0.35mL 0.18mL |
8.82mL 1.76mL 0.88mL |
17.65mL 3.53mL 1.76mL |
参考文献 |
---|